Even though the article doesn't mention us, I think it sheds light on why management has spent time on updating their CAR-T patent, and on merging with Baudax/TeraImmune. We're on the right track, maybe even making the track.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.